Welcome
Support Centre
03 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The influence of methylenetetrahydrofolate reductase C677T genotype and folate status on deoxyribonucleic acid methylation and uracil misincorporation in the colon of healthy volunteers
ISRCTN ISRCTN43577261
ClinicalTrials.gov identifier
Public title The influence of methylenetetrahydrofolate reductase C677T genotype and folate status on deoxyribonucleic acid methylation and uracil misincorporation in the colon of healthy volunteers
Scientific title
Acronym FolGene
Serial number at source JQADGAR
Study hypothesis Increasing folate status and the MethyleneTetraHydroFolate Reductase (MTHFR) C677T genotype influence intermediary biomarkers of preclinical neoplasia (DeoxyriboNucleic Acid [DNA] methylation and uracil misincorporation) in human colonic epithelium.
Ethics approval King's College Hospital Research Ethics Committee approval received 13 July 2006 (reference Number 06/Q0703/29).
Study design Randomised, double blind, placebo controlled, parallel study
Countries of recruitment United Kingdom
Disease/condition/study domain Colorectal cancer
Participants - inclusion criteria No lesions detected on full colonoscopy
Participants - exclusion criteria 1. Colorectal polyps or cancer discovered at present colonoscopy
2. Current or previous diagnosis of cancer, or a strong family history of colorectal cancer or adenomatous polyposis coli
3. Inflammatory bowel disease
4. Current or past history of gluten-sensitive enteropathy
5. Clinical and/or laboratory evidence of intestinal malabsorption
6. Significant renal or liver disease
7. Pregnancy
8. Epilepsy
9. Alcoholism
10. Pernicious anaemia
11. Serum vitamin B12 levels less than 180 ng/l and the use of medication known to antagonise the metabolism of folate
Anticipated start date 11/09/2006
Anticipated end date 11/09/2009
Status of trial Completed
Patient information material
Target number of participants 60
Interventions 400 µg per day folic acid or placebo for three months.
Primary outcome measure(s) Changes in genomic and gene specific DNA methylation and uracil misincorporation.
Secondary outcome measure(s) Changes in blood and tissue folate and plasma homocysteine.
Sources of funding Biotechnology and Biological Sciences Research Council (BBSRC) (reference number: BB/D523178/1)
Trial website
Publications
Contact name Dr  Maria  Pufulete
  Address King's College London
Franklin-Wilkins Building
150 Stamford Street
Waterloo
  City/town London
  Zip/Postcode SE1 9NH
  Country United Kingdom
  Tel +44 (0)20 7848 4270
  Fax +44 (0)20 7848 4185
  Email maria.pufulete@kcl.ac.uk
Sponsor Nutritional Sciences Research Division (UK)
  Address King's College London
Hodkin Building
Guy's Campus
  City/town London
  Zip/Postcode SE1 1UL
  Country United Kingdom
  Sponsor website: http://www.kcl.ac.uk
Date applied 04/08/2006
Last edited 06/10/2006
Date ISRCTN assigned 06/10/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central